STAT

HHS nominee Azar signals new line of attack on drug prices

Lawmakers are grilling Azar about his plans to bring down drug prices and his role in pricing decisions in his last job.
Alex Azar testifies during a Senate Finance Committee hearing on Tuesday. Source: Carolyn Kaster/AP

WASHINGTON — Alex Azar, Trump’s pick to lead the Health and Human Services Department, doubled down on his commitment to bringing down prescription drug prices Tuesday — and even added a new target for future policymaking: drug makers’ list prices.

Lawmakers at Azar’s confirmation hearing Tuesday before the Senate Finance Committee, like those at an earlier hearing before a separate panel, grilled him repeatedly about his plans, as president of Eli Lilly’s U.S. business.

You're reading a preview, sign up to read more.

More from STAT

STAT3 min read
Experimental Brain-controlled Hearing Aid Can Pick Out Voices In A Crowd
Researchers unveiled an experimental hearing aid that reads the mind, using artificial intelligence to separate the sounds of different speakers.
STAT3 min readSociety
A Smartphone App Could Help Diagnose Ear Infections More Accurately — And At Home
With a paper funnel and machine learning, a new smartphone app could help determine at home whether a child has an ear infection.
STAT4 min read
Pharma Is Making Progress Addressing Global Health, But It’s Still A Mixed Bag
Drug makers are taking steps to reach people on very low incomes, but access programs are for just a few diseases.